CN115998714B - 一种脂质纳米颗粒、递送***及递送***的制备方法 - Google Patents
一种脂质纳米颗粒、递送***及递送***的制备方法 Download PDFInfo
- Publication number
- CN115998714B CN115998714B CN202310266605.4A CN202310266605A CN115998714B CN 115998714 B CN115998714 B CN 115998714B CN 202310266605 A CN202310266605 A CN 202310266605A CN 115998714 B CN115998714 B CN 115998714B
- Authority
- CN
- China
- Prior art keywords
- mrna
- lipid
- bis
- delivery system
- dioleoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 46
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 53
- 239000002245 particle Substances 0.000 claims abstract description 19
- -1 cationic lipid Chemical class 0.000 claims abstract description 17
- 229960005486 vaccine Drugs 0.000 claims abstract description 10
- 108700021021 mRNA Vaccine Proteins 0.000 claims description 13
- 229940126582 mRNA vaccine Drugs 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- HSBMBJDVXFRTTD-UHFFFAOYSA-N C(CCCCC)C(C(=O)OCCCCCCOC(C(CCCCCCCC)CCCCCC)=O)CCCCCCCC Chemical compound C(CCCCC)C(C(=O)OCCCCCCOC(C(CCCCCCCC)CCCCCC)=O)CCCCCCCC HSBMBJDVXFRTTD-UHFFFAOYSA-N 0.000 claims description 8
- KDLSKKYZXNKGTK-LQDDAWAPSA-M trimethyl-[(z)-2-[(z)-octadec-9-enoyl]-4-oxohenicos-12-enyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)CC(C[N+](C)(C)C)C(=O)CCCCCCC\C=C/CCCCCCCC KDLSKKYZXNKGTK-LQDDAWAPSA-M 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 6
- 241001678559 COVID-19 virus Species 0.000 claims description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 239000012074 organic phase Substances 0.000 claims description 6
- 229950004354 phosphorylcholine Drugs 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 230000000975 bioactive effect Effects 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- SQRDXGHYNZDIBW-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCCCCCCCNC(C)=O Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCNC(C)=O SQRDXGHYNZDIBW-UHFFFAOYSA-N 0.000 claims description 3
- 239000012071 phase Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 241000726445 Viroids Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 229940088623 biologically active substance Drugs 0.000 claims 2
- 238000001476 gene delivery Methods 0.000 claims 1
- 239000002539 nanocarrier Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 abstract description 15
- 108091007433 antigens Proteins 0.000 abstract description 6
- 102000036639 antigens Human genes 0.000 abstract description 6
- 239000000427 antigen Substances 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 3
- 210000000987 immune system Anatomy 0.000 abstract description 3
- 230000008105 immune reaction Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 9
- 238000001890 transfection Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 125000002091 cationic group Chemical group 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108020003589 5' Untranslated Regions Proteins 0.000 description 4
- 108091036066 Three prime untranslated region Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 3
- 101150027674 S1 gene Proteins 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108091005609 SARS-CoV-2 Spike Subunit S1 Proteins 0.000 description 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000004815 dispersion polymer Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009525 mild injury Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310266605.4A CN115998714B (zh) | 2023-03-20 | 2023-03-20 | 一种脂质纳米颗粒、递送***及递送***的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310266605.4A CN115998714B (zh) | 2023-03-20 | 2023-03-20 | 一种脂质纳米颗粒、递送***及递送***的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115998714A CN115998714A (zh) | 2023-04-25 |
CN115998714B true CN115998714B (zh) | 2023-06-30 |
Family
ID=86028348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310266605.4A Active CN115998714B (zh) | 2023-03-20 | 2023-03-20 | 一种脂质纳米颗粒、递送***及递送***的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115998714B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117482240B (zh) * | 2024-01-03 | 2024-04-26 | 深圳大学总医院 | 一种rna疫苗递送制剂及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113402404A (zh) * | 2021-04-30 | 2021-09-17 | 江苏普瑞康生物医药科技有限公司 | 脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
WO2021250263A1 (en) * | 2020-06-11 | 2021-12-16 | Etherna Immunotherapies Nv | Lipid nanoparticles |
CN114404391A (zh) * | 2022-02-16 | 2022-04-29 | 深圳厚存纳米药业有限公司 | 一种纳米粒及其制备方法和用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7333563B2 (ja) * | 2018-01-18 | 2023-08-25 | イーザアールエヌーエー イムノセラピーズ エンヴェー | 脂質ナノ粒子 |
WO2021148511A1 (en) * | 2020-01-21 | 2021-07-29 | Etherna Immunotherapies Nv | Lipid nanoparticles |
US11241493B2 (en) * | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
BR112022019781A2 (pt) * | 2020-04-22 | 2022-12-13 | BioNTech SE | Vacina para o coronavírus |
US20230043677A1 (en) * | 2021-07-26 | 2023-02-09 | Oregon State University | Inhalable therapeutics |
CN114306279A (zh) * | 2021-12-30 | 2022-04-12 | 复旦大学 | 基于科罗索酸或其类似物的脂质纳米颗粒***及其制备方法和应用 |
CN115737535B (zh) * | 2022-08-19 | 2023-09-01 | 西北工业大学 | 一种可控降解纳米复合凝胶及其制备方法和应用 |
CN115444931A (zh) * | 2022-09-05 | 2022-12-09 | 浙江大学 | 均衡诱导抗病毒细胞与体液免疫的核酸-纳米乳的构建与应用 |
CN115154439B (zh) * | 2022-09-08 | 2022-12-09 | 南京澄实生物科技有限公司 | 一种mRNA脂质纳米颗粒递送***及其制备方法和应用 |
-
2023
- 2023-03-20 CN CN202310266605.4A patent/CN115998714B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021250263A1 (en) * | 2020-06-11 | 2021-12-16 | Etherna Immunotherapies Nv | Lipid nanoparticles |
CN113402404A (zh) * | 2021-04-30 | 2021-09-17 | 江苏普瑞康生物医药科技有限公司 | 脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
CN114404391A (zh) * | 2022-02-16 | 2022-04-29 | 深圳厚存纳米药业有限公司 | 一种纳米粒及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN115998714A (zh) | 2023-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240016738A1 (en) | Lipid nanoparticles | |
CN111467321A (zh) | 一种mRNA核酸类药物胞内递送***、制备方法和应用 | |
US5665380A (en) | Lipid vesicle fusion as a method of transmitting a biologically active material to a cell | |
WO1997000965A2 (en) | A lipidic vector for nucleic acid delivery | |
CN115998714B (zh) | 一种脂质纳米颗粒、递送***及递送***的制备方法 | |
US8883967B2 (en) | Branched amphipathic oligo-peptides that self-assemble into vesicles | |
US9675710B2 (en) | Lipid nanoparticles for gene therapy | |
EP3432868B1 (en) | Thin-shell polymeric nanoparticles and uses thereof | |
JP2023545886A (ja) | 脂質ナノ粒子 | |
Nogueira et al. | Membrane-destabilizing activity of pH-responsive cationic lysine-based surfactants: role of charge position and alkyl chain length | |
CN113825497A (zh) | 生产脂质体的方法 | |
CN110151701A (zh) | 杂化囊泡的制备方法及其制备得到的杂化囊泡、药物和应用 | |
CN110772635B (zh) | 流感病毒小体包被的仿生纳米疫苗及其制备方法 | |
KR20220145788A (ko) | 지질 나노입자의 제조 방법 및 이의 제조 장치 | |
JP4988114B2 (ja) | 生物学的材料の送達系 | |
CN113105625A (zh) | 一种琥珀酸维生素e修饰的聚乙烯亚胺衍生物、制备方法及其应用 | |
JP2004512352A (ja) | 荷電高分子を捕捉するデリバリーシステム及びその調製方法 | |
Kundu et al. | Development of nanosomes using high-pressure homogenization for gene therapy | |
CN116139108B (zh) | 一种脂质递送***及其所构成的类病毒结构疫苗 | |
CN109260157A (zh) | 一种正电荷多肽脂质体纳米制剂及其制备方法与应用 | |
KR100986604B1 (ko) | 신규한 아미노지질을 함유하는 에스아이알엔에이 수송용 유전자 조성물 및 제조방법 | |
CN112641757B (zh) | 一种用于跨膜递送分子的载体及其制备方法 | |
JP2008247855A (ja) | 物質を細胞内へ導入するために用いるエマルション及びそれを用いた物質導入方法 | |
CN116966163A (zh) | 一种核酸与多肽的制剂及其制备方法 | |
JP2014031349A (ja) | 結合剤及びその利用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230713 Address after: 650000 No. 2-1, floor 2, building B, Ciba biotechnology innovation center, Longquan Road, Panlong District, Kunming City, Yunnan Province Patentee after: Weirui Biotechnology (Kunming) Co.,Ltd. Patentee after: Shandong weigaolitong Biological Products Co.,Ltd. Address before: 650000 No. 2-1, floor 2, building B, Ciba biotechnology innovation center, Longquan Road, Panlong District, Kunming City, Yunnan Province Patentee before: Weirui Biotechnology (Kunming) Co.,Ltd. |
|
TR01 | Transfer of patent right |